Clinical Trial SWOG 1001
- A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
- Principal Investigator
- Jason Kaplan
- Status: CLOSED
- Study Type: Therapeutic, Treatment
- Protocol No:.SWOG 1001
- Limited (or early) Stage Diffuse Large B-cell Lymphoma (DLBCL) is curable in many people, but some still relapse, and some develop side-effects after treatment. This study uses a radiologic test called PET/CT scan after initial standard chemotherapy (R-CHOP) to help individualize subsequent treatment in the hope of improving cure rates while decreasing side effects of treatment.
- Standard chemotherapy "R-CHOP" for DLBCL will be followed up with a full body PET/CT scan to determine if there is active disease. If the PET/CT scan shows active lymphoma then those participants will receive more intensive treatment than those who have inactive disease after chemotherapy.
Some of the eligibility criteria include:
- Participant's diagnosis of Diffuse Large B-cell Lymphoma must have been proven by biopsy.
- Participants must be 18 years old or older.
- Participants must not have received prior chemotherapy, radiation or antibody therapy for lymphoma.
- Description of Treatment
- Participants will receive 3 cycles (21 days each) of standard chemotherapy called "R-CHOP" (FDA approved drugs doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab). After completing the 3 cycles of chemotherapy, participants will have a full body PET/CT scan. If the review of the PET/CT scan shows that disease is likely inactive, participants will receive an additional cycle (21 days) of R-CHOP for consolidation. If the review of the PET/CT scan shows that disease may still be active, then participants will receive radiation therapy to areas of the body with evidence of lymphoma, followed by a drug regimen called Yttrium-90 ibritumomab tiuxetan (Zevalin®). Follow-up visits will be every 6 months for 2 years and then yearly for a maximum of 7 years from the time participants entered the study.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jason Kaplan
- An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
- A Phase 1B, Multi-Center, Open Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B cell Lymphoma
- A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
- A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
- Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
- A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- A Phase II Study Of PNT2258 in Patients with Richter’s Transformation (RT)
last updated: 27-Nov-15 02:12 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.